Epigenetic Profiling for Early Detection and Treatment Response Monitoring in Non–Small Cell Lung Cancer: Protocol for a Prospective Translational Biomarker Study
JMIR Research Protocols · 27.08.2026 · 15 · e105338-e105338
DOI: 10.2196/105338 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift JMIR Research Protocols, online erschienen am 27.08.2026. Verfasst von Rajiv Kumar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Molecular Medicine, Faculty of Medicine - Dunedin, University of Otago, 58 Hanover Street, Hercus Building, Dunedin, 9016…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Early Detection of Cancer, Biomarkers, Tumor. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Non–small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide and continues to have poor survival outcomes, with most patients diagnosed at advanced stages of disease. In New Zealand, NSCLC contributes substantially to cancer inequities, with Māori communities experiencing disproportionately high incidence and mortality rates. Although low-dose computed tomography screening can improve early detection, major limitations remain, including false-positive findings, overdiagnosis, high infrastructure costs, and limited accessibility for rural and underserved populations. Liquid biopsy approaches using circulating tumor DNA (ctDNA), particularly DNA methylation profiling, have emerged as promising, minimally invasive strategies for improving cancer detection, treatment monitoring, and precision oncology.
Objective
This study aims to establish integrated genomic and epigenomic predictive and prognostic biomarkers using ctDNA, tumor tissue, and transcriptomic profiling to improve early detection, risk stratification, treatment selection and response prediction, and longitudinal monitoring, with particular emphasis on identifying molecular mechanisms associated with treatment resistance and disease progression.
Methods
This prospective observational translational biomarker study is being conducted through the University of Otago and associated respiratory and oncology services in New Zealand. The study will recruit participants with NSCLC (including squamous and nonsquamous subtypes), individuals referred to fast-track lung nodule assessment clinics, and nonmalignant respiratory controls. Serial peripheral blood sampling will be performed in selected participants at predefined clinical follow-up time points to evaluate treatment response and disease progression. The availability of formalin-fixed paraffin-embedded archival tissues will be recorded, but will not be mandatory for enrollment. Genome-scale DNA methylation profiling will be performed using cell-free reduced representation bisulfite sequencing (cfRRBS), while targeted genomic profiling and transcriptomic analyses will be conducted using targeted sequencing panels and RNA sequencing. Integrative bioinformatic analyses will be used to identify molecular biomarkers associated with early-stage disease, advanced disease, treatment response, and therapeutic resistance.
Results
Ethics approval for the study has been obtained from the New Zealand Health and Disability Ethics Committee (2022 EXP 12566). This study commenced in 2022, and recruitment and biospecimen collection are ongoing. The study aims to recruit approximately 450 participants, including patients with NSCLC, individuals referred through respiratory diagnostic pathways, and nonmalignant controls. As of July 31, 2026, 205 participants have been recruited, with recruitment continuing until the target sample size is reached. Molecular and data analyses are ongoing, with additional publications expected as the cohort matures.
Conclusions
This study will generate one of the first integrated genomic, epigenomic, and transcriptomic liquid biopsy datasets for NSCLC in New Zealand. The findings are expected to support the development of sensitive, accessible, and equitable blood-based biomarkers for NSCLC detection and treatment monitoring while also contributing to improved precision oncology approaches and reducing NSCLC inequities among Māori populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Molecular Medicine, Faculty of Medicine - Dunedin, University of Otago, 58 Hanover Street, Hercus Building, Dunedin, 9016, New Zealand, 64 210701558.
- Department of Medicine, Faculty of Medicine - Dunedin, University of Otago, Dunedin, New Zealand.
- Mercy Cancer Care, Mercy Hospital, Dunedin, New Zealand.
- Te Whatu Ora - Southern, Health New Zealand, Dunedin, New Zealand.
ORCID-Profile: Rajiv Kumar, Safia May Farry, Mark Ezegbogu, Glen Reid, Euan James Rodger, Ben Brockway, Aniruddha Chatterjee
Zitieren
APA
Kumar, R., Farry, S. M., Ezegbogu, M., Reid, G., Rodger, E. J., Brockway, B., & Chatterjee, A. (2026). Epigenetic Profiling for Early Detection and Treatment Response Monitoring in Non–Small Cell Lung Cancer: Protocol for a Prospective Translational Biomarker Study. JMIR Research Protocols, 15, e105338-e105338. https://doi.org/10.2196/105338
Vancouver
Kumar R, Farry SM, Ezegbogu M, Reid G, Rodger EJ, Brockway B, et al. Epigenetic Profiling for Early Detection and Treatment Response Monitoring in Non–Small Cell Lung Cancer: Protocol for a Prospective Translational Biomarker Study. JMIR Research Protocols. 2026;15:e105338-e105338. doi:10.2196/105338
BibTeX
@article{Kumar2026,
author = {Kumar, Rajiv and Farry, Safia May and Ezegbogu, Mark and Reid, Glen and Rodger, Euan James and Brockway, Ben and Chatterjee, Aniruddha},
title = {Epigenetic Profiling for Early Detection and Treatment Response Monitoring in Non–Small Cell Lung Cancer: Protocol for a Prospective Translational Biomarker Study},
journal = {JMIR Research Protocols},
year = {2026},
volume = {15},
pages = {e105338--e105338},
doi = {10.2196/105338}
}
EUVIMED